COVID-19 Updates

Visit UC San Diego's Coronavirus portal for the latest information for the campus community.

RESCUE-Drug: Rescuing OSA Patients Unable to Tolerate CAPAP Using Endotype-Targeted Drug Therapy

If you have questions about this study or wish to participate, please contact us at, or (858)246-2154. Alternatively, you may fill out our volunteer survey form so our research staff members can reach out to you. 

‚ÄčOur research team at UC San Diego is conducting a study to investigate the effect of combination therapy with three FDA-approved drugs (Diamox [acetazolamide], Lunesta [eszopiclone] +/- Effexor [venlafaxine]) on obstructive sleep apnea (OSA) severity. We are seeking volunteers who have been diagnosed with OSA for this 6-8 week study. 

Principal Investigator and Collaborator:

Christopher Schmickl, MD, PhD

Maximum compensation for completing entire study (exercises done over 6 weeks):



  • Age 18-65 years
  • Known or unknown diagnosis of OSA

What you may be asked to do during this study:

  • Home sleep test, if necessary, to determine presence and severity of OSA
  • Try 3 different combinations of 1-3 study drugs (or placebo). Each drug regimen will last 3 days
  • 3-4 in-clinic overnight visits to assess any changes in OSA severity
  • Perform a computerized reaction-time test
  • Complete study questionnaires 
  • Blood draw
  • For more detailed information, please read this study's Consent Documents or visit

    Back to Active Studies Page